BridgeBio Oncology Therapeutics, Inc. Accounts Payable and Other Accrued Liabilities
BridgeBio Oncology Therapeutics, Inc. (BBOT) had Accounts Payable and Other Accrued Liabilities of $9.69 thousand as of 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Balance Sheet › Liabilities › Accounts Payable and Accrued Liabilities
us-gaap:AccountsPayableAndOtherAccruedLiabilities · last filed 2024-05-15
- 2024-03-31: Accounts Payable and Other Accrued Liabilities $9.69K.
- 2023-03-31: Accounts Payable and Other Accrued Liabilities $0.00.
| Period end | Accounts Payable and Other Accrued Liabilities |
|---|---|
| 2024-03-31 | $9.69K 10-Q · filed 2024-05-15 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |